nl-asxl3-001
Nucleic acidexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 19, 2025 (NCT07197268)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Putative Polycomb group protein ASXL3ANTISENSE INHIBITOR
ASXL3 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07197268 | Phase 1/Phase 2 (Phase 2) | May 19, 2025 | n-Lorem Foundation, University of North Carolina at Chapel Hill |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| n-Lorem Foundation | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1